



**Vaccines and Global Health: The Week in Review**  
**18 July 2020 :: Number 560**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday evening at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. This blog allows full-text searching of over 9,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director*

*Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

**Contents** *[click on link below to move to associated content]*

A. [Milestones :: Perspectives :: Featured Journal Content](#)

B. [Emergencies](#)

C. [WHO; CDC \[U.S., Africa, China\]](#)

D. [Announcements](#)

E. [Journal Watch](#)

F. [Media Watch](#)



## ***Milestones :: Perspectives :: Research***

### **WHO and UNICEF warn of a decline in vaccinations during COVID-19**

#### *News release*

GENEVA/NEW YORK, 15 July 2020 – The World Health Organization and UNICEF warned today of an alarming decline in the number of children receiving life-saving vaccines around the world. This is due to disruptions in the delivery and uptake of immunization services caused by the COVID-19 pandemic. According to new data by WHO and UNICEF, these disruptions threaten to reverse hard-won progress to reach more children and adolescents with a wider range of vaccines, which has already been hampered by a decade of stalling coverage.

The latest data on vaccine coverage estimates from WHO and UNICEF for 2019 shows that improvements such as the expansion of the HPV vaccine to 106 countries and greater protection for children against more diseases are in danger of lapsing. For example, **preliminary data for the first four months of 2020 points to a substantial drop in the number of children completing three doses of the vaccine against diphtheria, tetanus and pertussis (DTP3). This is the first time in 28 years that the world could see a reduction in DTP3 coverage – the marker for immunization coverage within and across countries.**

“Vaccines are one of the most powerful tools in the history of public health, and more children are now being immunized than ever before,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “But the pandemic has put those gains at risk. The avoidable suffering and death caused by children missing out on routine immunizations could be far greater than COVID-19 itself. But it doesn’t have to be that way. Vaccines can be delivered safely even during the pandemic, and we are calling on countries to ensure these essential life-saving programmes continue.”

#### *COVID-19 disruptions*

**Due to the COVID-19 pandemic, at least 30 measles vaccination campaigns were or are at risk of being cancelled**, which could result in further outbreaks in 2020 and beyond.

According to a new UNICEF, WHO and Gavi pulse survey, conducted in collaboration with the US Centers for Disease Control, the Sabin Vaccine Institute and Johns Hopkins Bloomberg School of Public Health, **three quarters of the 82 countries that responded reported COVID-19 related disruptions in their immunization programmes as of May 2020.**

The reasons for disrupted services vary. Even when services are offered, people are either unable to access them because of reluctance to leave home, transport interruptions, economic hardships, restrictions on movement, or fear of being exposed to people with COVID-19. Many health workers are also unavailable because of restrictions on travel or redeployment to COVID response duties as well as a lack of protective equipment.

“COVID-19 has made previously routine vaccination a daunting challenge,” said UNICEF Executive Director Henrietta Fore. “We must prevent a further deterioration in vaccine coverage and urgently resume vaccination programs before children’s lives are threatened by other diseases. We cannot trade one health crisis for another.”...



## **COVAX - [More than 150 countries engaged in COVID-19 vaccine global access facility](#)**

*:: Seventy-five countries submit expressions of interest to COVAX Facility, joining up to 90 further countries which could be supported by the COVAX Advance Market Commitment (AMC)  
:: The COVAX Facility, and the AMC within it, is designed to guarantee rapid, fair and equitable access to COVID-19 vaccines for every country in the world, rich and poor, to make rapid progress towards slowing the pandemic*

*:: Interest from governments representing more than 60% of the world's population offers 'tremendous vote of confidence' in the effort to ensure truly global access to COVID-19 vaccines, once developed*

Geneva/London, 15 July 2020 – **Seventy-five countries have submitted expressions of interest to protect their populations and those of other nations through joining the COVAX Facility**, a mechanism designed to guarantee rapid, fair and equitable access to COVID-19 vaccines worldwide.

**The 75 countries, which would finance the vaccines from their own public finance budgets, partner with up to 90 lower-income countries that could be supported through voluntary donations to Gavi's COVAX Advance Market Commitment (AMC).**

Together, this group of up to 165 countries represents more than 60% of the world's population. Among the group are representatives from every continent and more than half of the world's G20 economies.

"COVAX is the only truly global solution to the COVID-19 pandemic," said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. "For the vast majority of countries, whether they can afford to pay for their own doses or require assistance, it means receiving a guaranteed share of doses and avoiding being pushed to the back of the queue, as we saw during the H1N1 pandemic a decade ago. Even for those countries that are able to secure their own agreements with vaccine manufacturers, this mechanism represents, through its world-leading portfolio of vaccine candidates, a means of reducing the risks associated with individual candidates failing to show efficacy or gain licensure."

The COVAX Facility forms a key part of the COVAX pillar (COVAX) of the Access to COVID-19 Tools (ACT) Accelerator, a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO, working in partnership with developed and developing country vaccine manufacturers. COVAX aims to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world.

It will achieve this by sharing the risks associated with vaccine development, investing in manufacturing upfront so vaccines can be deployed at scale as soon as they are proven successful, and pooling procurement and purchasing power to achieve sufficient volumes to end the acute phase of the pandemic by 2021.

"This early level of interest represents a tremendous vote of confidence in COVAX and our shared goal to protect people around the globe through the fair allocation of a COVID-19 vaccine," said Dr Richard Hatchett, CEO of CEPI. "COVAX offers an innovative solution to the gravest public health crisis in living memory. It will speed up the availability of safe and effective vaccines through early investment in manufacturing capacity, and maximise the chances of success by backing a broad and diverse portfolio of vaccine candidates. Through COVAX our aspiration is to be able to vaccinate the most vulnerable 20% of the population of every country that participates, regardless of income level, by the end of 2021. Ensuring fair access is not only a matter of equity; it is the fastest way to end this pandemic"

**The goal of COVAX is by the end of 2021 to deliver two billion doses of safe, effective vaccines that have passed regulatory approval and/or WHO prequalification.** These vaccines will be delivered equally to all participating countries, proportional to their populations, initially prioritising healthcare workers then expanding to cover 20% of the population of participating countries. Further doses will then be made available based on country need, vulnerability and COVID-19 threat. The COVAX Facility will also maintain a buffer of doses for emergency and humanitarian use, including dealing with severe outbreaks before they spiral out of control.

"The COVID-19 pandemic, like every health crisis, also presents us with opportunities," said Dr Soumya Swaminathan, WHO Chief Scientist. "A vaccine that is affordable and accessible to all will help us address systemic health inequalities. We need all countries to support COVAX to achieve this goal and bring an end to the acute phase of the pandemic."

The success of these efforts will ultimately depend on securing enough funding from governments and commitments from vaccine manufacturers to participate at a scale large enough to deliver a global solution. **The formal expressions of interest submitted are non-binding;** the COVAX pillar will now begin a process of consultation with all 165 countries, with countries funding vaccines through their own domestic budgets being required to provide an upfront payment and a commitment to purchase doses by the end of August to secure involvement in the COVAX Facility.

Significant progress has been achieved by the COVAX partners to date, with seven of the nine candidate vaccines supported by CEPI already in clinical trials. A memorandum of understanding with AstraZeneca also commits them to supply 300 million doses of COVID-19 vaccines to COVAX.

In addition, in June Gavi [launched](#) the COVAX Advance Market Commitment (AMC), a financing instrument aimed at incentivising vaccine manufacturers to produce sufficient quantities of eventual COVID-19 vaccines to ensure access for developing countries. The Gavi COVAX AMC has already raised close to US\$ 600 million against an initial target of US\$ 2 billion from high income donors as well as the private sector. Gavi will also work with developing countries to assure readiness of supply and cold chain and training to reach high risk groups.

.....

**Project Syndicate**  
*Opinion*

## **The Fastest Way Out of the Pandemic**

Jul 15, 2020 [Seth Berkley](#) , [Richard Hatchett](#), [Soumya Swaminathan](#)

*During the 2009 swine flu pandemic, a few countries cornered the vaccine market, leaving the vast majority of the global population with no vaccine at all until the outbreak was effectively over. This scenario must be avoided at all costs during the current crisis – and, thanks to the COVID-19 Vaccine Global Access Facility, it can be.*

...COVAX employs a radically different approach. In addition to using “push” financing – direct investment in research, development, and manufacturing – it uses “pull” financing, in the form of advance purchase commitments for large numbers of doses upon licensure. This provides powerful incentives for the private sector to support urgent vaccine development.

Moreover, COVAX pools government resources to fund scaling up the most promising candidates even before clinical trials are completed. That way, when approval comes, large quantities of vaccine doses will be ready to go. Already, WHO is working with a range of stakeholders, including member states and civil-society organizations, to develop and implement a mechanism for equitable and fair allocation of vaccine doses, once they become available.

COVAX will support only vaccine candidates that are developed in accordance with the highest possible safety standards. By working with experts around the world to develop target product profiles, share best-practice testing models, facilitate multi-country clinical trials, and promote regulatory harmonization, COVAX will establish a new benchmark for rapid, safe, and efficacious vaccine development and delivery.

We cannot afford to leave our economies on their current path for much longer. As global GDP shrinks – the [International Monetary Fund](#) and the [World Bank](#) forecast about a 5% contraction in 2020 – poverty and hunger are rising sharply. With the world economy losing more than \$10 billion each day, shortening the pandemic by even a few days would more than offset the costs of COVAX. Global collaboration – where risks and benefits are shared equally – has never been a better value proposition.

.....  
.....

## **Featured Journal Content**

### **New England Journal of Medicine**

July 14, 2020

DOI: 10.1056/NEJMe2025111

*Editorial*

### **The Covid-19 Vaccine-Development Multiverse**

Penny M. Heaton, M.D.

Leaving in its wake more than 12 million infections, over 550,000 deaths, and an economic toll in the trillions of dollars to date,<sup>[1](#)</sup> the SARS-CoV-2 pandemic has devastated the most vulnerable in our society — adults 65 years of age or older, persons with underlying conditions, and the economically deprived.<sup>[2](#)</sup> A vaccine is urgently needed to prevent Covid-19 and thereby stem complications and deaths resulting from transmission of the disease.

Jackson et al. now report in the Journal preliminary findings from a phase 1 trial to evaluate the safety and immunogenicity of an mRNA SARS-CoV-2 vaccine.<sup>3</sup> Phase 1 involves 45 healthy adults, 18 to 55 years of age, who were assigned to receive the candidate vaccine at one of three dose levels (25 µg, 100 µg, or 250 µg) given as two vaccinations 28 days apart. These preliminary findings represent the first of three reports of data from a phase 1 study of this candidate vaccine; a second report including similar data from adults older than 55 years of age and a final report summarizing the safety and durability of immunity for both study cohorts are also planned.

The speed with which this vaccine has been developed is remarkable — from publication of the first SARS-CoV-2 sequences through phase 1 in 6 months, as compared with a typical timeline of 3 to 9 years ([Figure 1](#)). The rapid pace of development of vaccines against Covid-19 is enabled by several factors: prior knowledge of the role of the spike protein in coronavirus pathogenesis and evidence that neutralizing antibody against the spike protein is important for immunity<sup>4,5</sup>; the evolution of nucleic acid vaccine technology platforms that allow creation of vaccines and prompt manufacture of thousands of doses once a genetic sequence is known<sup>6</sup>; and development activities that can be conducted in parallel, rather than sequentially, without increasing risks for study participants.

The safety and immunogenicity data in this preliminary report are promising, and they support continued development of this vaccine. However, we must bear in mind the complexity of vaccine development and the work still to be done before Covid-19 vaccines are widely available.

Many phase 3 studies fail because of incorrect identification of the dose that best balances safety and efficacy.<sup>7</sup> The dosing regimen for this mRNA vaccine is still under study. The 250-µg dose did not appear to be associated with markedly higher antibody titers than the 100-µg dose, but it was associated with a higher proportion of severe systemic adverse events. As the investigators indicate, it is prudent to evaluate doses of 100 µg and lower to define the regimen that provides the most appropriate benefit–risk profile for this vaccine. Another special dosing consideration in this case is age: the immune functions that decline with age and that are likely to be responsible for the greater risk of severe Covid-19 in older adults may also lead to poor vaccine responses. Will a high-dose Covid-19 vaccine be needed for effective protection of older adults, as observed with influenza vaccines?<sup>8</sup>

The clinical significance of SARS-CoV-2 binding and neutralizing antibody titers and their ability to predict efficacy will need to be confirmed. These measures are currently being used to guide dose selection before being verified; they are the best tools available and are supported by findings in nonhuman primates.<sup>9</sup> Confirmation of the correlation between antibody titers and protection against Covid-19 will be possible only in a large clinical efficacy study. In the meantime, the validity of the assays for measuring antibody will also need to be documented. These assays are notoriously variable because they use live virus or protein expression in cell culture with a readout that relies on an in vitro biologic reaction (i.e., serum antibodies binding or killing viral antigen). Optimization of the performance characteristics of these assays will be invaluable in streamlining further development and supporting bridging across varied populations and manufacturing processes.

The authors indicate that a planned phase 3 trial of this mRNA SARS-CoV-2 vaccine is imminent; the trial will require thousands of subjects in order to confirm the safety of the vaccine and to show statistically robust efficacy in preventing Covid-19. The operational complexity inherent in a large study is compounded by the undulations of the pandemic; efficacy can be determined only if there is a match between the location of vaccinated participants and pandemic hot spots. Uncertainty regarding the expected efficacy profile also drives complexity; the profiles observed for other viral vaccines suggest that efficacy against severe Covid-19 may be higher than efficacy against mild disease. Careful selection of primary end points and event-driven study designs with the possibility of sample size reestimation should be considered.

Accelerating the development of Covid-19 vaccine candidates beyond phase 1 depends on continued parallel tracking of activities and fulsome resources. The world has now witnessed the compression of 6 years of work into 6 months. Can the vaccine multiverse do it again, leading to a reality of a safe, efficacious Covid-19 vaccine for the most vulnerable in the next 6?

.....  
.....

## **EMERGENCIES**

### **Coronavirus [COVID-19]**

*Public Health Emergency of International Concern (PHEIC)*

#### **Situation report - 180** - WHO

Coronavirus disease 2019 (COVID-19)

18 July 2020

Confirmed cases :: 13 876 441 [week ago: 12 322 395]

Confirmed deaths :: 593 087 {week ago: 556 335}

#### ***Highlights***

:: WHO has published an interim checklist for local authorities on Practical actions in cities to strengthen preparedness for the COVID-19 pandemic and beyond. The checklist accompanies the interim guidance on Strengthening preparedness for COVID-19 in cities and urban settings.

:: The WHO Regional Office for Europe joined the International Labour Organization (ILO) and UNICEF to issue a policy paper on how to strengthen protection against, and address, social and economic shocks such as those caused by the pandemic.

: Ghana's nurses are delivering child healthcare services to communities in need amid COVID-19. Segla, a community nurse who provides preventive healthcare to children in the north of Accra, emphasized the importance of visiting households if pediatric patients do not attend clinics due to COVID-19.

.....

#### **A guide to WHO's guidance on COVID-19**



17 July 2020

.....

### **WHO urges greater COVID-19 health services in Africa's humanitarian settings**

16 July 2020

Brazzaville – The World Health Organization (WHO) today called for greater access to COVID-19 detection, testing and care among vulnerable populations grappling with the impacts of protracted conflict and humanitarian emergencies across Africa.

Sub-Saharan Africa is home to over 26% of the world's refugees. Long-running conflicts in regions like the Sahel have led to the closure of health facilities and the flight of health workers. In Burkina Faso, 110 health facilities have been closed due to insecurity while services have been impaired in 186 others, leaving around 1.5 million people without adequate health care. In Mali's central and northern regions, health services have been paralysed by persistent attacks. In 2019 alone, 18 attacks on health facilities were reported. So far this year, one health centre has been attacked.

"COVID-19 has exacerbated existing humanitarian challenges, particularly with regards to access to health services in many countries in the region," said Dr Matshidiso Moeti, WHO Regional Director for Africa. "With the pandemic, we have seen some humanitarian operations delayed due to lockdowns, curfews and the restrictions of movement for both personnel and cargo vital for COVID-19 response."

Crowded settings such as displacement camps can heighten the risk of COVID-19 transmission due to difficult access to clean water, leading to inadequate hygiene, and where physical distancing is almost impossible.

The United Nations system has activated health clusters in eight countries where the humanitarian situation requires support from the international community, including Burkina Faso, Central African Republic, Chad, the Democratic Republic of the Congo, Ethiopia, Mali, Niger and South Sudan. Although information on COVID-19 transmission in humanitarian settings remains limited so far, about 1800 COVID-19 cases have been reported in seven of these countries among the displaced, refugees, migrants or in areas affected by humanitarian crises. Due to the limited detection and testing capacity, the number is likely to be an under-estimate.

"WHO urges the humanitarian community and Member States to increase support to the millions of people in dire need of assistance in the region. If we don't step up health services, including testing, tracing, isolation and care for people already living in precarious settings and displacement camps, COVID-19 could spark untold tragedy," said Dr Moeti...

.....

### **Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2**

*Anticipated large, global Phase 2b/3 safety and efficacy study may begin as early as July 2020*  
July 13, 2020



NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--[Pfizer Inc.](#) (NYSE: PFE) and [BioNTech SE](#) (Nasdaq: BNTX, "BioNTech") today announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to help protect against SARS-CoV-2 (the virus that causes COVID-19), received Fast Track designation from the U.S. Food and Drug Administration (FDA). BNT162b1 and BNT162b2 are the two most advanced vaccine candidates in the BNT162 program currently being evaluated in ongoing Phase 1/2 clinical studies in the United States and Germany...

### **World's First Phase III Clinical Trial of COVID-19 Inactivated Vaccine Begins in UAE**

July 17, 2020

The first WHO enlisted global clinical Phase III trial of Sinopharm CNBG's inactivated vaccine to combat COVID-19 has started in Abu Dhabi, inspired by the UAE Leadership's commitment to overcome the...

.....  
.....

### **Emergencies**

#### **Ebola – DRC+**

*Public Health Emergency of International Concern (PHEIC)*

**Last *WHO Situation Report* published [23 June 2020](#)**

### **Democratic Republic of the Congo Ebola cases rise, surpass previous outbreak**

16 July 2020

Brazzaville – The Ebola outbreak in the Democratic Republic of the Congo's (DRC) Equateur Province continues to grow, causing major concern as the World Health Organization (WHO) and partners face critical funding gaps. Confirmed cases have now surpassed the total number recorded during the province's last outbreak in 2018.

The latest outbreak, DRC's 11th, was declared on 1 June 2020 after a cluster of cases was detected in Mbandaka area of Equateur Province. The outbreak has since spread to six health zones, with 56 cases recorded. The city of Mbandaka and its surroundings were also the site of the country's 9th Ebola outbreak which lasted from May to July 2018 and in which 54 cases were confirmed.

Of the 56 cases reported so far, 53 are confirmed and three are probable. In the last three weeks alone, 28 cases have been confirmed.

"Responding to Ebola in the midst of the ongoing COVID-19 pandemic is complex, but we must not let COVID-19 distract us from tackling other pressing health threats," said Dr Matshidiso Moeti, WHO Regional Director for Africa. "The current Ebola outbreak is running into headwinds because cases are scattered across remote areas in dense rain forests. This makes for a costly response as ensuring that responders and supplies reach affected populations is extremely challenging."

The ongoing Ebola response is also facing funding shortfalls. So far WHO has mobilized US\$ 1.75 million, which will last only a few more weeks. Additional support is needed to rapidly scale up the efforts by WHO, the DRC health authorities and partners to ensure all the affected

communities receive key services including health education and community engagement, vaccination, testing, contact tracing and treatment.

Significant achievements have been made since the outbreak began. In six weeks, more than 12 000 people have been vaccinated. During the 2018 outbreak in Equateur, it took two weeks to start vaccinations. This time around vaccinations started within four days of the outbreak being declared...

.....  
.....

## **Emergencies**

### **POLIO**

*Public Health Emergency of International Concern (PHEIC)*

#### **Polio this week as of 14 July 2020**

:: A virtual meeting of the Technical Advisory Group (TAG) on polio eradication in Pakistan was held on 11 and 15 of June 2020. The meeting report is now available [here](#).

:: The polio eradication programme has stepped up to help the Sudanese Ministry of Health limit spread of the COVID-19 virus. The programme is working in 14 states in the country supporting COVID-19 surveillance, information dissemination and training of health workers. [Read more...](#)

#### ***Summary of new WPV and cVDPV viruses this week (AFP cases and environmental samples):***

:: ***Afghanistan:*** four cVDPV2 cases

:: ***Pakistan:*** two WPV1 cases and seven WPV1 positive environmental samples

:: ***Angola:*** one cVDPV2 case

:: ***Cameroon:*** one cVDPV2 positive environmental sample

:: ***Chad:*** two cVDPV2 cases

:: ***Malaysia:*** one cVDPV1 positive environmental sample

.....  
.....

#### **WHO Grade 3 Emergencies** [to 18 July 2020]

##### **Somalia**

:: [Strengthening laboratory capacity in Somalia](#) 17 July 2020

[Democratic Republic of the Congo](#) - *No new digest announcements identified*

[Mozambique floods](#) - *No new digest announcements identified*

[Nigeria](#) - *No new digest announcements identified*

[South Sudan](#) - *No new digest announcements identified*

[Syrian Arab Republic](#) - *No new digest announcements identified*

[Yemen](#) - *No new digest announcements identified*

.....

## **WHO Grade 2 Emergencies** [to 18 July 2020]

Angola - *No new digest announcements identified*

Afghanistan - *No new digest announcements identified*

Burkina Faso [in French] - *No new digest announcements identified*

Burundi - *No new digest announcements identified*

Cameroon - *No new digest announcements identified*

Central African Republic - *No new digest announcements identified*

Ethiopia - *No new digest announcements identified*

Iraq - *No new digest announcements identified*

Libya - *No new digest announcements identified*

Malawi - *No new digest announcements identified*

Measles in Europe - *No new digest announcements identified*

MERS-CoV - *No new digest announcements identified*

Myanmar - *No new digest announcements identified*

Niger - *No new digest announcements identified*

occupied Palestinian territory - *No new digest announcements identified*

HIV in Pakistan - *No new digest announcements identified*

Sao Tome and Principe Necrotizing Cellulitis (2017) - *No new digest announcements identified*

Sudan - *No new digest announcements identified*

Ukraine - *No new digest announcements identified*

Zimbabwe - *No new digest announcements identified*

.....

## **WHO Grade 1 Emergencies** [to 18 July 2020]

Chad - *No new digest announcements identified*

Djibouti - *Page not responding at inquiry*

Kenya - *No new digest announcements identified*

Mali - *No new digest announcements identified*

Namibia - viral hepatitis - *No new digest announcements identified*

Tanzania - *No new digest announcements identified*

.....

.....

## **UN OCHA – L3 Emergencies**

*The UN and its humanitarian partners are currently responding to three 'L3' emergencies. This is the global humanitarian system's classification for the response to the most severe, large-scale humanitarian crises.*

### **Syrian Arab Republic**

:: Recent Developments in Northwest Syria - Situation Report No. 17 - As of 13 July 2020

### **Yemen**

:: 12 July 2020 Yemen: COVID-19 Preparedness and Response Monthly Report (June 2020)  
[EN/AR]

.....

## **UN OCHA – Corporate Emergencies**

*When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.*

### **East Africa Locust Infestation**

:: Desert Locust situation update - 13 July 2020

### **COVID-19**

:: (COVID-19) Situation Report 36: occupied Palestinian territory, issued 16 July 2020, information for period: 5 March - 16 July 2020

#### *Highlights*

:: The number of people testing positive for COVID-19 continues to surge in the West Bank with an average of 365 new cases per day since July 1

:: WHO has visited Hebron to consult with the governor and health teams on support priorities for this most affected governorate

#### *WHO preparedness, readiness and response*

:: WHO is continuing to work with partners to support Ministry of Health's (MoH) efforts to respond to the COVID-19 situation in the occupied Palestinian territory (oPt).

.....  
.....

### **WHO & Regional Offices** [to 18 July 2020]

16 July 2020

#### *News release*

**WHO Director-General pays tribute to Spain's sacrifices and leadership to confront COVID-19**

15 July 2020

#### *News release*

**More than 150 countries engaged in COVID-19 vaccine global access facility**

*[See Milestones above for detail]*

15 July 2020

#### *News release*

**WHO and UNICEF warn of a decline in vaccinations during COVID-19**

*[See Milestones above for detail]*

13 July 2020

#### *News release*

**As more go hungry and malnutrition persists, achieving Zero Hunger by 2030 in doubt, UN report warns**

.....

### **Weekly Epidemiological Record, 17 July 2020, vol. 95, 29 (pp. 337–348)**

:: Update on immunodeficiency-associated vaccine-derived polioviruses worldwide, July 2018–December 2019

:: Performance of acute flaccid paralysis (AFP) surveillance and incidence of poliomyelitis, 2020

.....

## **WHO Regional Offices**

*Selected Press Releases, Announcements*

### **WHO African Region AFRO**

:: WHO urges greater COVID-19 health services in Africa's humanitarian settings 16 July 2020

The World Health Organization (WHO) today called for greater access to COVID-19 detection, testing and care among vulnerable populations grappling with the impacts of protracted conflict and humanitarian emergencies across Africa.

:: Democratic Republic of the Congo Ebola cases rise, surpass previous outbreak 16 July 2020

:: Ghana's community nurses deliver child health care amid COVID-19 16 July 2020

A backpack containing simple but essential medicines and supplies is all Antoinette Nuselie Segla, principal community health nurse, needs to embark on a health outreach in Fadama, a populous community in the north of Ghana's capital, Accra.

### **WHO Region of the Americas PAHO**

:: PAHO Director calls for protection of health workers in face of the advancing COVID19 pandemic in the region of the Americas (04/07/2020)

:: Amid COVID-19 pandemic, new WHO report urges greater investments in the nursing workforce (04/07/2020)

### **WHO South-East Asia Region SEARO**

:: Maldives, Sri Lanka eliminate measles and rubella, ahead of 2023 target 8 July 2020 *News release*

### **WHO European Region EURO**

:: New WHO study shows how Ireland can reduce health-related financial hardship and unmet need by delivering universal access to health care 08-07-2020

:: WHO/Europe expert team reaches Turkmenistan to support the country's COVID-19 response 07-07-2020

### **WHO Eastern Mediterranean Region EMRO**

:: COVID-19 presents opportunities for greater collaboration on the SDGS, says WHO's Regional Director 8 July 2020

:: WHO delivers essential COVID-19 supplies to Afghanistan 5 July 2020

### **WHO Western Pacific Region**

*No new digest content identified*

.....

.....

**CDC/ACIP** [to 18 July 2020]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

*Latest News Releases*

**Cruise ship No Sail Order extended through September 2020** Thursday, July 16, 2020

**CDC Director Dr. Robert R. Redfield and HHS Chief Information Officer Jose Arrieta Remarks on HHS Protect** Thursday, July 16, 2020

**CDC calls on Americans to wear masks to prevent COVID-19 spread** Tuesday, July 14, 2020

Americans are increasingly adopting the use of cloth face masks to slow the spread of COVID-19, and the latest science may convince even more to do so.

In an editorial published today in the Journal of the American Medical Association (JAMA), CDC reviewed the latest science and affirms that cloth face coverings are a critical tool in the fight against COVID-19 that could reduce the spread of the disease, particularly when used universally within communities. There is increasing evidence that cloth face coverings help prevent people who have COVID-19 from spreading the virus to others...

**MMWR News Synopsis Friday, July 17, 2020**

Update on Immunodeficiency-Associated Vaccine-Derived Polioviruses — Worldwide, July 2018–December 2019

Mumps Cases Disproportionately Affecting Men Who Have Sex with Men and Persons Living with HIV Infection — Chicago, Illinois, 2018

Detection and Genetic Characterization of Community-Based SARS-CoV-2 Infections — New York City, March 2020

Symptom profiles of COVID-19 cases — United States, January–April 2020

Policy Note: Continuation of Mosquito Surveillance and Control during Public Health Emergencies and Natural Disasters

.....

**Africa CDC** [to 18 July 2020]

<http://www.africacdc.org/>

*News*

**Government of Japan supports Africa's Joint Continental Strategy for COVID-19 response**

ADDIS ABABA, ETHIOPIA, 16 JULY 2020. The Permanent Mission of Japan to the African Union has announced a donation of US\$ 1 million by the Government of Japan to the Africa Centres for Disease Control and Prevention (Africa CDC).

The grant is for implementing the Africa Joint Continental Strategy for COVID-19. It will be used to strengthen the capacity of Africa CDC Regional Collaboration Centres so they can support effective and efficient communication and knowledge exchange on COVID-19 among Member States, as well as to support infection prevention and control activities and improve clinical case management of COVID-19...

.....

## **China CDC**

<http://www.chinacdc.cn/en/>

*No new digest content identified.*

## **National Health Commission of the People's Republic of China**

<http://en.nhc.gov.cn/>

*News*

### **July 18: Daily briefing on novel coronavirus cases in China**

On July 17, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 22 new cases of confirmed infections.

### **Beijing: Number of medium-risk areas lowered to four**

2020-07-17

### **Beijing reports no new domestically transmitted COVID-19 cases for 10th day**

2020-07-16

.....  
.....

## **Announcements**

### **Paul G. Allen Frontiers Group** [to 18 July 2020]

<https://alleninstitute.org/what-we-do/frontiers-group/news-press/>

*News*

*No new digest content identified.*

### **BARDA – U.S. Department of HHS** [to 18 July 2020]

<https://www.phe.gov/about/barda/Pages/default.aspx>

*BARDA News*

*No new digest content identified.*

### **BMGF - Gates Foundation** [to 18 July 2020]

<http://www.gatesfoundation.org/Media-Center/Press-Releases>

*No new digest content identified.*

### **Bill & Melinda Gates Medical Research Institute** [to 18 July 2020]

<https://www.gatesmri.org/>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*NEJM*

*Editorial*



## **The Covid-19 Vaccine-Development Multiverse**

Penny M. Heaton, M.D.

*[See Milestones above for detail]*

### **CARB-X** [to 18 July 2020]

<https://carb-x.org/>

*CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.*

*No new digest content identified.*

### **CEPI – Coalition for Epidemic Preparedness Innovations** [to 18 July 2020]

<http://cepi.net/>

*Latest News*

#### **More than 150 countries engaged in COVID-19 Vaccine Global Access Facility**

Interest from governments represents more than 60% of the world's population.

COVID-19

15 Jul 2020

*[See Milestones above for detail]*

#### **University of Queensland vaccine becomes seventh CEPI-supported COVID-19 vaccine candidate to enter clinical trials**

The first participants were today enrolled into a Phase 1 clinical trial of the University of Queensland's candidate vaccine.

Blog

13 Jul 2020

### **EDCTP** [to 18 July 2020]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*Latest news*

*No new digest content identified.*

### **Emory Vaccine Center** [to 18 July 2020]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

#### **mRNA Vaccine Against SARS-CoV-2 Preliminary Report**

### **European Medicines Agency** [to 18 July 2020]

<http://www.ema.europa.eu/ema/>

*News & Press Releases •*

*No new digest content identified.*

**European Vaccine Initiative** [to 18 July 2020]

<http://www.euvaccine.eu/>

*Latest News*

*No new digest content identified.*

**FDA** [to 18 July 2020]

<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm>

*Press Announcements*

[July 18, 2020 - Coronavirus \(COVID-19\) Update: FDA Issues First Emergency Authorization for Sample Pooling in Diagnostic Testing](#)

[July 17, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup July 17, 2020](#)

[July 16, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup July 16, 2020](#)

[July 15, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup July 15, 2020](#)

[July 14, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup July 14, 2020](#)

[July 13, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup July 13, 2020](#)

**Fondation Merieux** [to 18 July 2020]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 18 July 2020]

<https://www.gavi.org/>

*News releases*

15 July 2020

[More than 150 countries engaged in COVID-19 vaccine global access facility](#)

*[See Milestones above detail]*

**GHIT Fund** [to 18 July 2020]

<https://www.ghitfund.org/newsroom/press>

*GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that*

*No new digest content identified.*

**Global Fund** [to 18 July 2020]

<https://www.theglobalfund.org/en/news/>

*No new digest content identified.*

**Hilleman Laboratories** [to 18 July 2020]

<http://www.hillemanlabs.org/>

*No new digest content identified.*

**Human Vaccines Project** [to 18 July 2020]

<http://www.humanvaccinesproject.org/media/press-releases/>

*No new digest content identified.*

**IAVI** [to 18 July 2020]

<https://www.iavi.org/newsroom>

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest content identified.*

**IFFIm**

<http://www.iffim.org/>

*Announcements*

*No new digest content identified.*

**IFRC** [to 18 July 2020]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Selected Press Releases, Announcements*

*Asia Pacific, Bangladesh, India, Pakistan*

**[Red Cross Red Crescent braces for COVID spike in South Asia](#)**

Kuala Lumpur/Delhi/Islamabad/Dhaka/Geneva, 16 July 2020 – South Asia is fast becoming the next COVID-19 epicentre as cases soar in India, Pakistan and Bangladesh. John Fleming, Asia Pacific Head of Health, International Federation of Red Cross and Red ...

16 July 2020

*Afghanistan, Asia Pacific*

**[Race to avert COVID-19 caused catastrophes in Afghanistan](#)**

Kabul/Kuala Lumpur/Geneva, 14 July 2020: Afghanistan is on the edge of potential health, social and economic catastrophes caused by COVID-19 as the disease places a crippling burden on one of the ten most fragile states in the world. More than 34,000 p ...  
14 July 2020

**IVAC** [to 18 July 2020]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates*

**Webinar: Responding to the Impact of COVID-19 on Refugees**

July 2020

*Register:* The International Vaccine Access Center (IVAC) on July 29, 2020 at 1pm ET will host a 60-minute webinar, "Responding to the Impact of COVID-19 on Refugees."

Description: The concern for refugee populations and their risk to preventable diseases during the COVID-19 pandemic is high. Refugee camps are home to concentrated groups of people with limited access to health services – making the spread of disease easy but the delivery of treatments difficult. Existing vaccines offer vulnerable populations a critical piece of preventative medicine, especially to children who suffer most during a humanitarian crisis. Disease modeling and humanitarian health experts at JHU will discuss what impact COVID-19 will have in terms of infections and outcomes in refugee camps, and the response needed to protect children with routine immunizations and a potential COVID-19 vaccine.

[Register Here](#)

**IVI** [to 18 July 2020]

<http://www.ivi.int/>

*Selected IVI News & Announcements*

*No new digest content identified.*

**JEE Alliance** [to 18 July 2020]

<https://www.jeealliance.org/>

*Selected News and Events*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 18 July 2020]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Philippines*

**Displaced communities in Marawi living with COVID-19 and ongoing un...**

Project Update 17 Jul 2020

*Belgium*

**Left behind in the time of COVID-19**

Report 17 Jul 2020

*Burkina Faso*

**Displaced in Burkina Faso face extra challenges amid increasing violence and rain**

Project Update 16 Jul 2020

*Greece*

**Greek government must end lockdown for locked up people on Greek islands**

Project Update 16 Jul 2020

*Iraq*

**Displaced people are extremely vulnerable to COVID-19 in Iraq**

Press Release 14 Jul 2020

*Greece*

**Vulnerable refugees evicted and left to sleep on streets**

Press Release 13 Jul 2020

**National Vaccine Program Office - U.S. HHS [to 18 July 2020]**

<https://www.hhs.gov/vaccines/about/index.html>

*NVAC 2020 Meetings*

**September 23-24, 2020 Meeting (Virtual)**

**NIH [to 18 July 2020]**

<http://www.nih.gov/news-events/news-releases>

*Selected News Releases*

**Experimental COVID-19 vaccine safe, generates immune response**

July 14, 2020 — NIH-sponsored Phase 1 trial tested mRNA vaccine.

An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well tolerated and prompted neutralizing antibody activity in healthy adults, according to interim results published online today in The New England Journal of Medicine....

**Placenta lacks major molecules used by SARS-CoV-2 virus to cause infection**

July 14, 2020 — NIH study may help explain why the virus has rarely been found in fetuses or newborns of women with COVID-19.

**PATH [to 18 July 2020]**

<https://www.path.org/media-center/>

*Selected Announcements*

*No new digest content identified.*

**Sabin Vaccine Institute [to 18 July 2020]**

<http://www.sabin.org/updates/pressreleases>

*Statements and Press Releases*

**Sabin's President of Global Immunization Dr. Bruce Gellin Testifies at House Briefing on Approval Processes for Safe, Effective COVID-19 Vaccine**

Bruce Gellin, M.D., M.P.H., president of Global Immunization at the Sabin Vaccine Institute (Sabin) and former Deputy Assistant Secretary for Health and Director of the National Vaccine Program Office at the U.S. Department of Health and Human Services (HHS), testified on July, 14, 2020, at the House Subcommittee on Economic and Consumer Policy's briefing entitled "Guardrails to Ensure a Safe and Effective COVID-19 Vaccine."

**UNAIDS** [to 18 July 2020]

<http://www.unaids.org/en>

*Selected Press Releases/Reports/Statements*

17 July 2020

**Fostering an economy of kindness through traditional bartering in Fiji**

14 July 2020

**Delivering antiretroviral medicines to homes in Côte d'Ivoire and Nigeria**

**UNICEF** [to 18 July 2020]

<https://www.unicef.org/media/press-releases>

*Selected Press releases/Announcements*

*Press release*

07/15/2020

**WHO and UNICEF warn of a decline in vaccinations during COVID-19**

WHO and UNICEF call for immediate efforts to vaccinate all children as new data shows that, before the COVID-19 pandemic, vaccine coverage stalled at 85 per cent for nearly a decade, with 14 million unvaccinated infants yearly

*Press release*

07/13/2020

**As more go hungry and malnutrition persists, achieving Zero Hunger by 2030 in doubt, UN report warns**

Securing healthy diets for the billions who cannot afford them would save trillions in costs

**Unitaid** [to 18 July 2020]

<https://unitaid.org/>

*Featured News*

*No new digest content identified.*

**Vaccination Acceptance Research Network (VARN)** [to 18 July 2020]

<https://vaccineacceptance.org/news.html#header1-2r>

*Announcements*

*No new digest content identified.*

**Vaccine Confidence Project** [to 18 July 2020]

<http://www.vaccineconfidence.org/>

*Latest News & Archive*

**Event: [Vaccine confidence in the time of COVID-19](#)**

*The VCP will be launching a new Lancet publication analysing 5 years of global vaccine confidence trends & discussing the implications for new COVID-19 vaccines*

22nd July, 2-3.30pm (BST)

This webinar will mark the launch of a five-year analysis of vaccine confidence data to be published in the Lancet on July 21st (23:30 BST embargo). "Spatio-temporal trends in vaccine confidence: a global analysis exploring volatility, polarization, and trust." is a valuable mapping of the current global vaccine confidence landscape and trends. This webinar will present the key findings and highlights from the study and discuss the implications for the introduction of potential COVID-19 vaccines.

Register [here](#).

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 18 July 2020]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*No new digest content identified.*

**Wellcome Trust** [to 18 July 2020]

<https://wellcome.ac.uk/news>

*Opinion* | 14 July 2020

**[How could COVID-19 change research culture for the better?](#)**

Ben Bleasdale

Senior Policy Adviser Wellcome

COVID-19 is transforming every aspect of society – and research is no exception. But how can we use what we’ve learned in the past six months to build a better research culture?

**The Wistar Institute** [to 18 July 2020]

<https://www.wistar.org/news/press-releases>

*Press Released*

*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 18 July 2020]

<https://www.wfpha.org/>

*Latest News*

*No new digest content identified.*

**World Organisation for Animal Health (OIE)** [to 18 July 2020]

<https://www.oie.int/en/for-the-media/press-releases/2020/>

*Press Releases*

*No new digest content identified.*

.....



**ARM [Alliance for Regenerative Medicine]** [to 18 July 2020]

<https://alliancerm.org/press-releases/>

*Press Releases*

*No new digest content identified.*

**BIO** [to 18 July 2020]

<https://www.bio.org/press-releases>

*Press Releases*

**BIO CEO Defends Dr. Fauci, Says Criticisms “Undermine Our Response to this Pandemic”**

July 16, 2020

In response to attacks on Dr. Anthony Fauci’s credibility and character, BIO President and CEO Dr. Michelle McMurry-Heath issued the following statement: “As this global pandemic continues to wreak havoc, we must stand behind the scientists and...

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 18 July 2020]

<http://www.dcvmn.org/>

*News; Upcoming events*

**WEBINAR: Defining the concept on fair pricing for medicines**

21 July 2020

**IFPMA** [to 18 July 2020]

<http://www.ifpma.org/resources/news-releases/>

*Selected Press Releases, Statements, Publications*

*No new digest content identified.*

**ICBA – International Council of Biotechnology Associations** [to 18 July 2020]

<https://internationalbiotech.org/>

*News*

*No new digest content identified.*

**PhRMA** [to 18 July 2020]

<http://www.phrma.org/>

*Selected Press Releases, Statements*

**R&D Focus: 5 things to know about the biopharmaceutical research ecosystem**

Jocelyn Ulrich | July 13, 2020 |

America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent years, rapid advances in scientific discovery have ushered in a new era of medicine, transforming our ability to treat, and in some cases cure, some of the most challenging diseases, including cancer, rare diseases and autoimmune conditions. These advancements are due to the productivity of the United States’ biomedical research ecosystem,

which is sustained by a policy framework that is designed to support and advance America's leadership in the innovation of new medicines.

\* \* \* \*

### ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **American Journal of Infection Control**

July 2020 Volume 48, Issue 7, p733-858

<http://www.ajicjournal.org/current>

[Reviewed earlier]

### **American Journal of Preventive Medicine**

July 2020 Volume 59, Issue 1, p1-148

<http://www.ajpmonline.org/current>

[Reviewed earlier]

### **American Journal of Public Health**

July 2020 110(7)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 103, Issue 1, July 2020

<http://www.ajtmh.org/content/journals/14761645/103/1>

[Reviewed earlier]

### **Annals of Internal Medicine**

7 July 2020 Volume 173, Issue 1

<http://annals.org/aim/issue>

*Latest*

16 July 2020

*Original Research*

### **Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19**

Caleb P. Skipper, MD, et al

There is no known effective oral therapy for early COVID-19. This randomized, double-blind, placebo-controlled trial evaluated effects of oral hydroxychloroquine on symptoms and disease severity in adult outpatients with early COVID-19.

#### *Editorials*

### **The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale**

Neil W. Schluger, MD

In their article, Skipper and colleagues report the results of trial of hydroxychloroquine for patients presenting with nonsevere COVID-19. The editorialists discuss the findings and the need to examine carefully not only what we know about hydroxychloroquine and COVID-19 but also how we learned it, disseminated it, and put it into practice.

### **Artificial Intelligence – An International Journal**

Volume 285 August 2020

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/285/suppl/C>

[Reviewed earlier]

### **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 18 July 2020)

[No new digest content identified]

### **BMJ Global Health**

July 2020 - Volume 5 - 7

<https://gh.bmj.com/content/5/7>

[Reviewed earlier]

### **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 18 July 2020)

[No new digest content identified]

### **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 18 July 2020)

### **Rotavirus group A genotype circulation patterns across Kenya before and after nationwide vaccine introduction, 2010–2018**

*Kenya introduced the monovalent G1P [8] Rotarix® vaccine into the infant immunization schedule in July 2014. We examined trends in rotavirus group A (RVA) genotype distribution pre- (January 2010–June 2014) an...*

Authors: Mike J. Mwanga, Betty E. Owor, John B. Ochieng, Mwanajuma H. Ngama, Billy Ogwel, Clayton Onyango, Jane Juma, Regina Njeru, Elijah Gicheru, Grieven P. Otieno, Sammy Khagayi, Charles N. Agoti, Godfrey M. Bigogo, Richard Omore, O. Yaw Addo, Seheri Mapaseka...

Citation: BMC Infectious Diseases 2020 20:504

Content type: Research article

Published on: 13 July 2020

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 18 July 2020)

[No new digest content identified]

### **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 18 July 2020)

**[Systems and implementation science should be part of the COVID-19 response in low resource settings](#)**

Authors: Mike English, Mosa Moshabela, Jacinta Nzinga, Edwine Barasa, Benjamin Tsofa, Bruno Marchal and Margaret E Kruk

Citation: BMC Medicine 2020 18:219

Content type: Commentary

Published on: 15 July 2020

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 18 July 2020)

[No new digest content identified]

### **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 18 July 2020)

**[The role of the Stop Transmission of Polio \(STOP\) program in developing countries: the experience of Kenya](#)**

*In 1988, the 41st World Health Assembly (WHA) marked the launch of the Global Polio Eradication Initiative (GPEI) for the eradication of polio. A key component of the GPEI has been the development and deployment ...*

Authors: Brook Tesfaye, Jeevan K. Makam, Kibet Sergon, Iheoma Onuekwusi, Charles Muitherero and Alieu Sowe

Citation: BMC Public Health 2020 20:1110

Content type: Research article

Published on: 14 July 2020

**[Parental awareness and utilization of meningococcal serogroup B vaccines in the United States](#)**

*Meningococcal serogroup B (MenB) is the most common cause of invasive meningococcal disease (IMD) in the United States. The US Advisory Committee on Immunization Practices (ACIP) recommends vaccination of heal...*

Authors: Amit Srivastava, Amanda Dempsey, Alex Galitsky, Mansour Fahimi and Liping Huang

Citation: BMC Public Health 2020 20:1109

Content type: Research article

Published on: 14 July 2020

### **Barriers to childhood immunization in sub-Saharan Africa: A systematic review**

*Immunization to prevent infectious diseases is a core strategy to improve childhood health as well as survival. It remains a challenge for some African countries to attain the required childhood immunization c...*

Authors: Joseph Benjamin Bangura, Shuiyuan Xiao, Dan Qiu, Feiyun Ouyang and Lei Chen

Citation: BMC Public Health 2020 20:1108

Content type: Research article

Published on: 14 July 2020

### **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 18 July 2020)

[No new digest content identified]

### **BMJ Open**

July 2020 - Volume 10 - 7

<https://bmjopen.bmj.com/content/10/7>

[Reviewed earlier]

### **Bulletin of the World Health Organization**

Volume 98, Number 7, July 2020, 441-508

<https://www.who.int/bulletin/volumes/98/7/en/>

[Reviewed earlier]

### **Child Care, Health and Development**

Volume 46, Issue 4 Pages: 397-536 July 2020

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

### **Clinical Pharmacology & Therapeutics**

Volume 108, Issue 1 Pages: 1-161 July 2020

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/2020/108/1>

Editorial Free Access

### **COVID-19: A Defining Moment for Clinical Pharmacology?**

Piet H. van der Graaf, Kathleen M. Giacomini

Pages: 11-15  
First Published: 29 April 2020

### **Clinical Therapeutics**

June 2020 Volume 42, Issue 6, p959-1136, e101-e114  
<http://www.clinicaltherapeutics.com/current>  
[Reviewed earlier]

### **Clinical Trials**

Volume 17 Issue 3, June 2020  
<https://journals.sagepub.com/toc/ctja/17/3>  
[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>  
[Accessed 18 July 2020]  
[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 94 July 2020  
<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/94/suppl/C>  
[New issue; No digest content identified]

### **The CRISPR Journal**

Volume 3, Issue 3 / June 2020  
<https://www.liebertpub.com/toc/crispr/3/3>  
[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 8, Issue 2, June 2020  
<https://link.springer.com/journal/40142/8/2>  
[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

August 2020 - Volume 33 - Issue 4  
<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>  
[Reviewed earlier]

### **Developing World Bioethics**

Volume 20, Issue 2 Pages: 61-114 June 2020

<https://onlinelibrary.wiley.com/toc/14718847/current>  
[Reviewed earlier]

### **Development in Practice**

Volume 30, Issue 4, 2020

<http://www.tandfonline.com/toc/cdip20/current>  
[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 14 - Issue 2 - April 2020

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>  
[Reviewed earlier]

### **Disasters**

Volume 44, Issue 3 Pages: 433-618 July 2020

<https://onlinelibrary.wiley.com/toc/14677717/current>  
[Reviewed earlier]

### **EMBO Reports**

Volume 21 Issue 7 3 July 2020

<https://www.embopress.org/toc/14693178/current>  
[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 26, Number 7—July 2020

<http://wwwnc.cdc.gov/eid/>  
[Reviewed earlier]

### **Epidemics**

Volume 31 June 2020

<https://www.sciencedirect.com/journal/epidemics/vol/31/suppl/C>  
[Reviewed earlier]

### **Epidemiology and Infection**

Volume 148 - 2020

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>  
[Reviewed earlier]

### **Ethics & Human Research**



Volume 42, Issue 4 Pages: 1-40 July–August 2020

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Pregnant Women Covid-19 Vaccine Challenge Trials Lotteries***

*Articles*

**The Pathway Forward: Insights on Factors that Facilitate Research with Pregnant Women**

Anna C. Mastroianni, Robert Franceschini, Sarah L. Wicks, Leslie Meltzer Henry

Pages: 2-16

First Published: 16 July 2020

*Articles*

*Free Access*

**Pregnant Women in Trials of Covid-19: A Critical Time to Consider Ethical Frameworks of Inclusion in Clinical Trials**

Ruth Farrell, Marsha Michie, Rachel Pope

Pages: 17-23

First Published: 20 June 2020

**Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events**

Nir Eyal

Pages: 24-34

First Published: 22 May 2020

**Advantages of Using Lotteries to Select Participants for High-Demand Covid-19 Treatment Trials**

Alexander A. Iyer, Saskia Hendriks, Annette Rid

Pages: 35-40

First Published: 22 June 2020

**The European Journal of Public Health**

Volume 30, Issue 3, June 2020

<https://academic.oup.com/eurpub/issue/30/3>

[Reviewed earlier]

**Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 18 July 2020]

*Open Letter metrics* Awaiting Peer Review

**Supporting communities of practice – A Journey to effective problem-solving** [version 1; peer review: awaiting peer review]

Christina Hanschke, James Baer, Alok Gangaramany, Janneke Verheijen, Nduku Kilonzo, Bryan Okiya, Leonard Kibe Ranji, Stephen Amolo Amolo, Simon Zwane, Rejoice Nkambule, Violet Buluma, Sylvia Ojoo, Susan Kim, Sharon Kibwana, Mark Dybul, Steve Kretschmer

Peer Reviewers Invited

Funder

Bill and Melinda Gates Foundation  
PUBLISHED 17 Jul 2020

*Open Letter metrics* AWAITING PEER REVIEW

**[How to engage communities on a large scale? Lessons from World Mosquito Program in Rio de Janeiro, Brazil](#)** [version 1; peer review: awaiting peer review]

Guilherme B. Costa, Ruth Smithyman, Scott L. O'Neill, Luciano A. Moreira

Peer Reviewers Invited

Funders

Bill and Melinda Gates Foundation

Ministério da Saúde Brasil

PUBLISHED 17 Jul 2020

Open Letter metrics AWAITING PEER REVIEW

**[Direct and indirect effects of COVID-19 on perinatal outcomes in low- and middle-income countries](#)** [version 1; peer review: awaiting peer review]

Felisita Tupou Ratu, Kathleen Ryan, Netsanet Workneh Gidi, Ilisapeci Vereti, Tsinuel Girma, Jeremy Oats, Ingrid Bucens, Alexandra Robinson, Claire von Mollendorf, Fiona M. Russell

Peer Reviewers Invited

Funder

Bill and Melinda Gates Foundation

PUBLISHED 16 Jul 2020

## **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 18 July 2020]

[No new digest content identified]

## **Global Health Action**

Volume 12, 2019 Issue 1

<https://www.tandfonline.com/toc/zgha20/12/sup1?nav=tocList>

[Reviewed earlier]

## **Global Health: Science and Practice (GHSP)**

2020 | Volume 8 | Number 2 June 30, 2020

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

## **Global Public Health**

Volume 15, 2020 Issue 7

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

## **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 18 July 2020]

### **Circulating vaccine-derived poliovirus: a menace to the end game of polio eradication**

Authors: Long Chiau Ming, Zahid Hussain, Siang Fei Yeoh, David Koh and Kah Seng Lee

Content type: Letter to the Editor

16 July 2020

The World Health Organisation Western Pacific Region countries were declared free of polio in 2000 until a polio outbreak involving 305 cases occurred in Indonesia in 2006. It was not until 2014 that the World Health Organisation South East Asia region was officially declared polio-free again. However, in February 2019, the Global Polio Eradication Initiative announced a new circulating vaccine-derived poliovirus outbreak in the Papua province of Indonesia. To make matter worse, the outbreak responses were tardy and led to transmission among migrating communities to other cities. The pressing regional issues of polio outbreak caused by circulating vaccine-derived poliovirus and use of oral polio vaccine have not been well presented. Our letter highlighted the suboptimal outbreak responses as well as the necessity of cross-border vaccination to curb continued poliovirus transmission.

## **Health Affairs**

Vol. 39, No. 7 July 2020

<https://www.healthaffairs.org/toc/hlthaff/current>

### ***Food, Income, Work & More***

*Interview Culture Of Health*

### **Tackling Social Determinants Of Health Around The Globe**

Alan R. Weil

*Open Access*

## **Health and Human Rights**

Volume 22, Issue 1, June 2020

<https://www.hhrjournal.org/volume-22-issue-1-june-2020/>

### ***Special Section: Mental Health and Human Rights***

[Reviewed earlier]

## **Health Economics, Policy and Law**

Volume 15 - Issue 3 - July 2020

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

## **Health Policy and Planning**

Volume 35, Issue 6, July 2020

<https://academic.oup.com/heapol/issue/35/5>

[Reviewed earlier]

## **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 18 July 2020]

[No new digest content identified]

## **Human Gene Therapy**

Volume 31, Issue 11-12 / June 2020

<https://www.liebertpub.com/toc/hum/31/11-12>

[Reviewed earlier]

## **Humanitarian Exchange Magazine**

Number 77, March 2020

<https://odihpn.org/magazine/responding-to-ebola-in-the-democratic-republic-of-congo/>

### ***Responding to Ebola in the Democratic Republic of Congo***

by Humanitarian Practice Network

This edition of Humanitarian Exchange, co-edited with Anne Harmer, focuses on the response to the Ebola outbreak in the Democratic Republic of Congo (DRC). Although at the time of publication the outbreak appeared to have ended, over its course it claimed 2,200 lives, with more than 3,300 infected, making this the world's second largest outbreak ever.

In the lead article, Natalie Roberts reflects on the extent to which humanitarian actors have applied learning from the outbreak in West Africa in 2014–2016. Richard Kojan and colleagues report on the NGO ALIMA's flexible, patient-centred approach to reducing mortality, Marcela Ascuntar reflects on lessons learned from community feedback and Bernard Balibuno, Emanuel Mbuna Badjonga and Howard Mollett highlight the crucial role faith-based organisations have played in the response. In their article, Theresa Jones, Noé Kasali and Olivia Tulloch outline the work of the Bethesda counselling centre in Beni, which provides support to grieving families. Reflecting on findings from a recent assessment by Translators without Borders, Ellie Kemp describes the challenges involved in providing clear and accessible information on Ebola and the response, and Sung Joon Park and colleagues explain how humane care and treatment can help increase trust and confidence in the response. Stephen Mugamba and his co-authors highlight the importance of community involvement in Ebola research, and Gillian McKay and her co-authors examine the impact of the Ebola outbreak and response on sexual and reproductive health services.

Stacey Mearns, Kiryn Lanning and Michelle Gayer present an Ebola Readiness Roadmap to support NGOs in preparing for an outbreak, while Edward Kumakech, Maurice Sadlier, Aidan Sinnott and Dan Irvine report on a Gap Analysis tool looking at the communication, community engagement and compliance tracking activities that need to be in place before an Ebola vaccine is deployed. Emanuele Bruni and colleagues describe the development of a new monitoring and evaluation framework for strategic response planning. The edition ends with an article by Adelicia Fairbanks, who argues for an acceptance strategy in the DRC to improve security and access for responding agencies.

## **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 16, Issue 6, 2020

<http://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

## **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/content>

[Accessed 18 July 2020]

[No new digest content identified]

## **Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>

[Accessed 18 July 2020]

### **Social innovation for health: engaging communities to address infectious diseases**

*Universal health coverage emphasises the value of the community-based delivery of health services to ensure that underserved populations have access to care. In areas where infectious diseases are endemic, the...*

Authors: Phyllis Dako-Gyeke, Uche V. Amazigo, Beatrice Halpaap and Lenore Manderson

Citation: Infectious Diseases of Poverty 2020 9:98

Content type: Commentary

Published on: 18 July 2020

### **Estimation of exponential growth rate and basic reproduction number of the coronavirus disease 2019 (COVID-19) in Africa**

*Since the first case of coronavirus disease 2019 (COVID-19) in Africa was detected on February 14, 2020, the cumulative confirmations reached 15 207 including 831 deaths by April 13, 2020. Africa has been desc...*

Authors: Saliyu S. Musa, Shi Zhao, Maggie H. Wang, Abdurrazzaq G. Habib, Umar T. Mustapha and Daihai He

Citation: Infectious Diseases of Poverty 2020 9:96

Content type: Research Article

Published on: 16 July 2020

## **International Health**

Volume 12, Issue 4, July 2020

<https://academic.oup.com/inthealth/issue/12/4>

[Reviewed earlier]

## **International Journal of Community Medicine and Public Health**

Vol 7, No 7 (2020) July 2020

<https://www.ijcmph.com/index.php/ijcmph/issue/view/64>

[Reviewed earlier]

**International Journal of Epidemiology**

Volume 49, Issue Supplement\_1, April 2020

[https://academic.oup.com/ije/issue/49/Supplement\\_1](https://academic.oup.com/ije/issue/49/Supplement_1)

***Big Data, Small Area***

[Reviewed earlier]

**International Journal of Human Rights in Healthcare**

Volume 13 Issue 3 2020

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/13/iss/3>

***Table of Contents***

[Reviewed earlier]

**International Journal of Infectious Diseases**

July 2020 Volume 96, p1-714

[https://www.ijidonline.com/issue/S1201-9712\(20\)X0008-7](https://www.ijidonline.com/issue/S1201-9712(20)X0008-7)

***Coronavirus (COVID-19) Collection*****[Coronavirus 2019 and health systems affected by protracted conflict: The case of Syria](#)**

Aula Abbara, Diana Rayes, Ola Fahham, Omar Alrashid Alhiraki, Munzer Khalil, Abdulrahman Alomar, Ahmad Tarakji

p192–195

Published online: May 7, 2020

**[COVID-19 and religious congregations: Implications for spread of novel pathogens](#)**

Sayed A. Quadri

p219–221

Published online: May 7, 2020

**[Mitigating lockdown challenges in response to COVID-19 in Sub-Saharan Africa](#)**

Leonard E.G. Mboera, George O. Akipede, Amitava Banerjee, Luis E. Cuevas, Thomas Czypionka, Mishal Khan, Richard Kock, David McCoy, Blandina T. Mmbaga, Gerald Misinzo, Elizabeth H. Shayo, Meru Sheel, Calvin Sindato, Mark Urassa

p308–310

Published online: May 10, 2020

**JAMA Network****[COVID-19 Update](#)** July 18, 2020

*These articles on COVID-19 were published across the JAMA Network in the last week.*

**JAMA**

July 14, 2020, Vol 324, No. 2, Pages 121-206

<https://jamanetwork.com/journals/jama/currentissue>

***Viewpoint*****[Monoclonal Antibodies for Prevention and Treatment of COVID-19](#)**

Mary Marovich, MD; John R. Mascola, MD; Myron S. Cohen, MD  
free access has multimedia

JAMA. 2020;324(2):131-132. doi:10.1001/jama.2020.10245

This Viewpoint discusses the potential role of neutralizing monoclonal antibodies (MAbs) as a treatment for coronavirus disease 2019 (COVID-19) and as a means of prevention in high-risk populations, and it also raises possible limitations of the approach that need to be disproven or addressed for the strategy to be effective.

*COVID-19: Beyond Tomorrow*

### **The Urgency and Challenge of Opening K-12 Schools in the Fall of 2020**

Joshua M. Sharfstein, MD; Christopher C. Morpew, PhD

free access has active quiz has multimedia has audio

JAMA. 2020;324(2):133-134. doi:10.1001/jama.2020.10175

This Viewpoint proposes a policy framework for reopening of US primary, middle, and high schools (kindergarten through 12th grade) in fall 2020, including ramping up community public health responses in the summer, symptom screening of students, and privileging return-to-school decisions for younger children and others at risk for education disparities.

[Audio Author Interview:](#) Coronavirus Q&A: Opening School in the Fall

[Audio Author Interview:](#) The Next COVID-19 Phase

### **Regulating Medicines in a Globalized World With Increased Recognition and Reliance Among RegulatorsA National Academies Report**

Lawrence O. Gostin, JD; Alastair J. Wood, MD; Patricia A. Cuff, MS, MPH

JAMA. 2020;324(2):145-146. doi:10.1001/jama.2019.21793

This Viewpoint summarizes recommendations from a 2020 National Academies of Sciences, Engineering, and Medicine (NASEM) committee report on ways to improve regulatory oversight of drugs in an era of global pharmaceutical research and development.

### **Sustainability, Business, and Health**

George Serafeim, DBA; Amanda M. Rischbieth, PhD; Howard K. Koh, MD, MPH  
has audio

JAMA. 2020;324(2):147-148. doi:10.1001/jama.2020.8714

This Viewpoint discusses examples of how many private sector businesses have aligned their core missions with civil and human rights and sustainability reforms, and emphasizes the importance of engaging the sector in achieving public health goals and accelerating worldwide recovery from the COVID-19 pandemic.

### **JAMA Pediatrics**

July 2020, Vol 174, No. 7, Pages 633-736

<http://archpedi.jamanetwork.com/issue.aspx>

[Reviewed earlier]

### **JBI Database of Systematic Review and Implementation Reports**

June 2020 - Volume 18 - Issue 6

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]



**Journal of Adolescent Health**

July 2020 Volume 67, Issue 1, p1-144

[https://www.jahonline.org/issue/S1054-139X\(20\)X0006-1](https://www.jahonline.org/issue/S1054-139X(20)X0006-1)

[Reviewed earlier]

**Journal of Artificial Intelligence Research**

Vol. 68 (2020)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

**Journal of Community Health**

Volume 45, Issue 4, August 2020

<https://link.springer.com/journal/10900/45/4>

[Reviewed earlier]

**Journal of Development Economics**

Volume 145 June 2020

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/145/suppl/C>

[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**

Volume 15 Issue 3, July 2020

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

August 2020 - Volume 74 - 8

<https://jech.bmj.com/content/74/8>

*Commentary*

[Harnessing behavioural science in public health campaigns to maintain 'social distancing' in response to the COVID-19 pandemic: key principles](#) (8 May, 2020) Free

Chris Bonell, Susan Michie, Stephen Reicher, Robert West, Laura Bear, Lucy Yardley, Val Curtis, Richard Amlôt, G James Rubin

**Journal of Evidence-Based Medicine**

Volume 13, Issue 2 Pages: 89-177 May 2020

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

**Journal of Global Ethics**

Volume 16, Issue 1, 2020

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 31, Number 2, May 2020

<https://muse.jhu.edu/issue/42391>

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 22, Issue 4, August 2020

<https://link.springer.com/journal/10903/22/4>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 18, 2020\_ Issue 3

<https://www.tandfonline.com/toc/wimm20/current>

[New issue; No digest content identified]

**Journal of Infectious Diseases**

Volume 222, Issue 3, 1 August 2020

<https://academic.oup.com/jid/issue/222/3>

[Reviewed earlier]

**Journal of Medical Ethics**

July 2020 - Volume 46 - 7

<http://jme.bmj.com/content/current>

[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 7, Issue 2 (2020)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>

[Reviewed earlier]

**Journal of Pediatrics**

July 2020 Volume 222, p1-268

<http://www.jpeds.com/current>

[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

<https://joppp.biomedcentral.com/>

[Accessed 18 July 2020]

**[Unrealized potential of drug repositioning in europe during COVID-19 and beyond: a physician's perspective](#)**

*Drug repositioning is the scientific strategy of investigating existing drugs for additional clinical indications. The advantages of drug repositioning are that it benefits patients and that it adds new indica...*

Authors: A. B. Bayoumy, N. K. H. de Boer, A. R. Ansari, F. Crouwel and C. J. J. Mulder

Citation: Journal of Pharmaceutical Policy and Practice 2020 13:45

Content type: Review

Published on: 17 July 2020

**Journal of Public Health Management & Practice**

July/August 2020 - Volume 26 - Issue 4

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Public Health Policy**

Volume 41, Issue 2, June 2020

<https://link.springer.com/journal/41271/41/2>

[Reviewed earlier]

**Journal of Refugee & Global Health**

Volume 2, Issue 2 (2019)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

**Journal of the Royal Society – Interface**

July 2020 Volume 17 Issue 168

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

**Journal of Travel Medicine**

Volume 27, Issue 4, May 2020

<https://academic.oup.com/jtm/issue/27/4>

*Editorial*

**[Successful smallpox eradication: what can we learn to control COVID-19?](#)**

D L Heymann, MD, Profeseor, Annelies Wilder-Smith, MD, Professor

Journal of Travel Medicine, Volume 27, Issue 4, May 2020, taaa090,

<https://doi.org/10.1093/jtm/taaa090>

The public health community needs to learn from history and needs to regain its ability to do shoe-leather public health. If we come together collectively and use the public health tools that

we have at hand, we will be successful in containing COVID-19 despite geopolitical tensions, just as we were successful in eradicating smallpox despite the Cold War at the time.

*Original Article*

**Meningococcal and pneumococcal carriage in Hajj pilgrims: findings of a randomized controlled trial**

Al-Mamoon Badahdah, PhD, Marwan A Bakarman, FFCM, Ameneh Khatami, MD, Mohamed Tashani, PhD, Osamah Barasheed, MPH ...

Journal of Travel Medicine, Volume 27, Issue 4, May 2020, taaa032,  
<https://doi.org/10.1093/jtm/taaa032>

**Journal of Virology**

July 2020; Volume 94, Issue 14

<http://jvi.asm.org/content/current>

[Reviewed earlier]

**The Lancet**

Jul 18, 2020 Volume 396 Number 10245 p143-212, e2-e5

<https://www.thelancet.com/journals/lancet/issue/current>

*Editorial*

**No more normal**

The Lancet

*Comment*

**The Lancet–Chatham House Commission on improving population health post COVID-19**

Harry Rutter, Richard Horton, Theresa M Marteau

**The Lancet Child & Adolescent Health**

Jul 2020 Volume 4 Number 7 p479-554, e17-e25

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

**Lancet Digital Health**

Jul 2020 Volume 2 Number 7 e331-e379

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

**Lancet Global Health**

Jul 2020 Volume 8 Number 7 e860-e972

<http://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

**Lancet Infectious Diseases**

Jul 2020 Volume 20 Number 7 p755-874, e148-e179

<http://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

**Lancet Public Health**

Jul 2020 Volume 5 Number 7 e361-e413

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

**Lancet Respiratory Medicine**

Jun 2020 Volume 8 Number 6 p527-646, e43-e54

<http://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

**Maternal and Child Health Journal**

Volume 24, Issue 7, July 2020

<https://link.springer.com/journal/10995/24/7>

[Reviewed earlier]

**Medical Decision Making (MDM)**

Volume 40 Issue 4, May 2020

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

**The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 98, Issue 2 Pages: 223-617 June 2020

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

**Nature**

Volume 583 Issue 7816, 16 July 2020

[http://www.nature.com/nature/current\\_issue.html](http://www.nature.com/nature/current_issue.html)

*Editorial* | 14 July 2020

**[Time to revise the Sustainable Development Goals](#)**

The pandemic has set back efforts to achieve the original 2015 targets. The need for change to make them more attainable is stronger than ever.

**Nature Biotechnology**

Volume 38 Issue 7, July 2020

<https://www.nature.com/nbt/volumes/38/issues/7>

***Focus on CRISPR tools and therapies***

[Reviewed earlier]

**Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 18 July 2020)

[No new digest content identified]

**Nature Genetics**

Volume 52 Issue 7, July 2020

<https://www.nature.com/ng/volumes/52/issues/7>

[Reviewed earlier]

**Nature Medicine**

Volume 26 Issue 7, July 2020

<https://www.nature.com/nm/volumes/26/issues/7>

*Comment* | 11 June 2020

**[Socio-demographic and epidemiological consideration of Africa's COVID-19 response: what is the possible pandemic course?](#)**

Africa is said to be the next possible hotspot for COVID-19. However, we believe this is still preventable.

Bamba Gaye, Stéphanie Khoury[...] & Xavier Jouven

*Comment* | 11 June 2020

**[COVID-19 in Africa: the spread and response](#)**

Given the current trends in incidence and underlying healthcare systems vulnerabilities, Africa could become the next epicenter of the COVID-19 pandemic. As the pandemic transitions to more widespread community transmission, how can the lessons learned thus far be consolidated to effectively curb the spread of COVID-19 while minimizing social disruption and negative humanitarian and economic consequences?

Marguerite Massinga Loembé, Akhona Tshangela[...] & John N. Nkengasong

**Nature Reviews Genetics**

Volume 21 Issue 7, July 2020

<https://www.nature.com/nrg/volumes/21/issues/7>

[Reviewed earlier]

**Nature Reviews Immunology**

Volume 20 Issue 7, July 2020

<https://www.nature.com/nri/volumes/20/issues/7>

[Reviewed earlier]

**Nature Reviews Drug Discovery**

Volume 19 Issue 7, July 2020

<https://www.nature.com/nrd/volumes/19/issues/7>

[Reviewed earlier]

**New England Journal of Medicine**

July 16, 2020 Vol. 383 No. 3

<http://www.nejm.org/toc/nejm/medical-journal>

*Perspective*

**[Africa in the Path of Covid-19](#)**

Wafaa M. El-Sadr, M.D., M.P.H., M.P.A., and Jessica Justman, M.D.

**Pediatrics**

Vol. 146, Issue 1 1 Jul 2020

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

**Pharmaceutics**

Volume 12, Issue 6 (June 2020) – 114 articles

<https://www.mdpi.com/1999-4923/12/5>

[Reviewed earlier]

**PharmacoEconomics**

Volume 38, Issue 7, July 2020

<https://link.springer.com/journal/40273/38/7>

[New issue; No digest content identified]

**PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 18 July 2020)

[No new digest content identified]

**PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 18 July 2020)

[No new digest content identified]

**PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 18 July 2020)

**[Disproportionate impact of the COVID-19 pandemic on immigrant communities in the United States](#)**

Eva Clark, Karla Fredricks, Laila Woc-Colburn, Maria Elena Bottazzi, Jill Weatherhead  
Viewpoints | published 13 Jul 2020 PLOS Neglected Tropical Diseases  
<https://doi.org/10.1371/journal.pntd.0008484>

**PLoS One**

<http://www.plosone.org/>

[Accessed 18 July 2020]

**[Retraction: Improving measles vaccine uptake rates in Nigeria: An RCT evaluating the impact of incentive sizes and reminder calls on vaccine uptake](#)**

Steven Brownstone, Alison Connor, Daniel Stein, the PLOS ONE Editors

**Retraction** | published 14 Jul 2020 PLOS ONE

<https://doi.org/10.1371/journal.pone.0236542>

**PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 18 July 2020]

[No new digest content identified]

**PNAS - Proceedings of the National Academy of Sciences of the United States of America**

<http://www.pnas.org/content/early/>

[No new digest content identified]

**Prehospital & Disaster Medicine**

Volume 35 - Issue 3 - June 2020

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

**Preventive Medicine**

Volume 136 July 2020

<https://www.sciencedirect.com/journal/preventive-medicine/vol/136/suppl/C>

[Reviewed earlier]

**Proceedings of the Royal Society B**

08 July 2020 Volume 287 Issue 1930

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]



**Public Health**

Volume 183 Pages 1-152 (June 2020)

<https://www.sciencedirect.com/journal/public-health/vol/183/suppl/C>

[Reviewed earlier]

**Public Health Ethics**

Volume 12, Issue 3, November 2019

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

**Public Health Reports**

Volume 135 Issue 3, May/June 2020

<https://journals.sagepub.com/toc/phrg/135/3>

[Reviewed earlier]

**Qualitative Health Research**

Volume 30 Issue 9, July 2020

<http://qhr.sagepub.com/content/current>

[Reviewed earlier]

**Research Ethics**

Volume 16 Issue 1-2, January-April 2020

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

**Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 18 July 2020]

[No new digest content identified]

**Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

[No new digest content identified]

**Risk Analysis**

Volume 40, Issue 7 Pages: 1321-1506 July 2020

<https://onlinelibrary.wiley.com/toc/15396924/current>

[New issue; No digest content identified]

## **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 18 July 2020]

[No new digest content identified]

## **Science**

17 July 2020 Vol 369, Issue 6501

<http://www.sciencemag.org/current.dtl>

*Letters*

### **[COVID-19 policies: Remember measles](#)**

By Debarati Guha-Sapir, Maria Moitinho de Almeida, Mory Keita, Gregg Greenough, Eran Bendavid

Science 17 Jul 2020 : 261

Nearly 120 million children in 37 countries are at risk of missing their measles-containing vaccine (MCV) shots this year, as preventive and public health campaigns take a back seat to policies put in place to contain coronavirus disease 2019 (COVID-19) ([1](#)). In March, the World Health Organization (WHO) issued guidelines indicating that mass vaccination campaigns should be put on hold to maintain physical distancing and minimize COVID-19 transmission ([2](#)). The disruption of immunization services, even for short periods, will lead to more susceptible individuals, more communities with less than the 95% MCV coverage needed for herd immunity, and therefore more measles outbreaks globally. A mere 15% decrease in routine measles vaccinations—a plausible result of lockdowns and disruption of health services—could raise the burden of childhood deaths by nearly a quarter of a million in poorer countries ([3](#)). Solutions for COVID-19, especially among the global poor, cannot include forgoing vaccinations.

Suspending mass vaccination campaigns is particularly pernicious in countries embroiled in conflict. Malnutrition among children and mothers in these regions is all too common—and increases mortality for those also infected by measles ([4](#)). In the conflict-affected regions of Ituri and North Kivu in eastern Democratic Republic of the Congo (DRC) alone, COVID-19 precautions are expected to delay measles vaccinations for nearly a million children ([1](#)).

COVID-19 mortality has so far been low in most poorer countries and trivial compared with the immediate risk of mortality due to measles. In the DRC, for example, the total number of deaths due to COVID-19 as of June was 37 ([5](#)), whereas the 2019 measles outbreak in the conflict region of eastern DRC killed more than 6000 people in a matter of months, mostly children ([6](#)). In some poor countries, more than 40% of the population is younger than 14 years old ([7](#)). This demographic group is the least affected by COVID-19 (in terms of symptoms, mortality, and transmission) ([8](#)) but at serious risk of measles ([9](#)). In addition, because many people in these countries live in cramped housing with unavoidable crowding, policies to minimize COVID-19 at the expense of measles prevention may not even be effective ([10](#)).

Postponement of measles campaigns prioritizes panic-driven policies for controlling COVID-19 without consideration of these policies' costs. If children are not immunized within the correct age window, they forgo benefits of lifelong immunity ([11](#)). Whole cohorts of children may be left unprotected. We must balance priorities of containing COVID-19 with efforts to control other high-transmission disease threats in poor countries, especially those affected by conflict.

### **Science Translational Medicine**

15 July 2020 Vol 12, Issue 552

<https://stm.sciencemag.org/>

[New issue; No digest content identified]

### **Social Science & Medicine**

Volume 255 June 2020

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/255/suppl/C>

[Reviewed earlier]

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 18 July 2020]

#### **[Maternal and perinatal outcomes and pharmacological management of Covid-19 infection in pregnancy: a systematic review protocol](#)**

*Over 4.2 million confirmed cases and more than 285,000 deaths, COVID-19 pandemic continues to harm significant number of people worldwide. Several studies have reported the impact of COVID-19 in general popula...*

Authors: Binny Thomas, Abdulrouf Pallivalapila, Wessam El Kassem, Asma Tarannum, Fatema Al Hail, Mohammed Rijims, Hussain Parappil, Arabo Ibrahim Bayo, Shamsa Ahmad, Zachariah Nazar, Derek Stewart and Moza Al Hail

Citation: Systematic Reviews 2020 9:161

Content type: Protocol

Published on: 18 July 2020

### **Travel Medicine and Infectious Diseases**

Volume 35 May–June 2020

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/35/suppl/C>

[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 25, Issue 7 Pages: i-iv, 751-904 July 2020

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

### **Vaccine**

Volume 38, Issue 32 Pages 4917-5076 (6 July 2020)

<https://www.sciencedirect.com/journal/vaccine/vol/38/issue/32>

Conference info Open access

#### **[WHO working group meeting to develop WHO Recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines](#)**

Dianliang Lei, Elwyn Griffiths, Javier Martin

*Discussion Abstract only*

**Vaccine handling and administration errors should be addressed to improve vaccine program safety**

Lee M. Hampton

*Research article Abstract only*

**HPV vaccine coverage and acceptability among a national sample of sexual minority women ages 18–45**

Paul L. Reiter, Gabriela Bustamante, Annie-Laurie McRee

*Research article Open access*

**Cost-effectiveness of pneumococcal vaccination for elderly in Sweden**

Ellen Wolff, Jann Storsaeter, Åke Örtqvist, Pontus Nacler, ... Adam Roth

*Research article Abstract only*

**Community needs and preferences for community pharmacy immunization services**

Noha Al Aloola, Raghad Alsaif, Hiba Alhabib, Abdulaziz Alhossan

*Research article Open access*

**Economic evaluation of rotavirus vaccination in children of Bhutan**

Pempa, Alia Cynthia G. Luz, Nantasit Luangasanatip, Pritaporn Kingkaew, ... Frédéric Debellut

## **Vaccines — Open Access Journal**

<http://www.mdpi.com/journal/vaccines>

(Accessed 18 July 2020)

*Open Access Review*

**Human Papillomavirus Vaccines: An Updated Review**

by Liqin Cheng , Yan Wang and Juan Du

Vaccines 2020, 8(3), 391; <https://doi.org/10.3390/vaccines8030391> (registering DOI) - 16 Jul 2020

Abstract

Human papillomavirus (HPV) vaccines, which were introduced in many countries in the past decade, have shown promising results in decreasing HPV infection and related diseases, such as warts and precancerous lesions. In this review, we present the updated information about current HPV vaccines...

## **Value in Health**

June 2020 Volume 23, Issue 6, p677-826

[https://www.valueinhealthjournal.com/issue/S1098-3015\(20\)X0008-8](https://www.valueinhealthjournal.com/issue/S1098-3015(20)X0008-8)

[Reviewed earlier]

\*

\*

\*

\*

## **Media/Policy Watch**

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

### **The Atlantic**

<http://www.theatlantic.com/magazine/>

*Accessed 18 July 2020*

[No new, unique, relevant content]

### **BBC**

<http://www.bbc.co.uk/>

*Accessed 18 July 2020*

#### **Russia's UK ambassador rejects coronavirus vaccine hacking allegations**

Russia's representative in the UK also dismisses suggestions of interference in British politics.  
18 Jul 2020

### **The Economist**

<http://www.economist.com/>

*Accessed 18 July 2020*

[No new, unique, relevant content]

### **Financial Times**

<http://www.ft.com/home/uk>

*Accessed 18 July 2020*

*Interview Coronavirus treatment*

#### **World must pick sides in vaccines battle, says Russian wealth fund chief**

*Kirill Dmitriev says his country will be among those to develop a vaccine soon*

The head of Russia's sovereign wealth fund said his country and a handful of other leading powers would develop viable Covid-19 vaccines in the new year, forcing the rest of the world to choose which of them to align with. Kirill Dmitriev, chief executive of the state-run Russian Direct Investment Fund, also warned that public health could be put at risk and coronavirus immunity divided by geopolitical faultlines if countries chose "political biases" instead of sourcing the most effective defences against the virus. "Six months from now, we will be in a situation where a few countries will have vaccines, and we believe those countries will be the UK, Russia, China and the US," Mr Dmitriev told the Financial Times in an interview. "And basically other countries will decide . . . which vaccine to buy . . . and who do you trust?"...

July 17, 2020

## **Forbes**

<http://www.forbes.com/>

*Accessed 18 July 2020*

[No new, unique, relevant content]

## **Foreign Affairs**

<http://www.foreignaffairs.com/>

*Accessed 18 July 2020*

*Snapshot*

### **Predicting the Next Pandemic**

The United States Needs an Early Warning System for Infectious Diseases

By Andrew S. Natsios

July 14, 2020

## **Foreign Policy**

<http://foreignpolicy.com/>

*Accessed 18 July 2020* | [No new, unique, relevant content]

*Argument*

### **The Coronavirus Pandemic Will Transform How Vaccines Are Made**

The COVID-19 crisis could enable the improvement of the global vaccine system for all diseases. Here's how that could happen.

By Saad B. Omer

| July 16, 2020, 12:50 PM

## **The Guardian**

<http://www.guardiannews.com/>

[No new, unique, relevant content]

## **New Yorker**

<http://www.newyorker.com/>

*Accessed 18 July 2020*

[No new, unique, relevant content]

## **New York Times**

<http://www.nytimes.com/>

*Accessed 18 July 2020*

*Health*

### **Mistrust of a Coronavirus Vaccine Could Imperil Widespread Immunity**

Billions are being poured into developing a shot, but the rapid timetable and President Trump's cheerleading are creating a whole new group of vaccine-hesitant patients.

By Jan Hoffman July 18

*Health*

### **Inside Johnson & Johnson's Nonstop Hunt for a Coronavirus Vaccine**

In Boston and in the Netherlands, scientists are racing to build a vaccine against the virus strangling the world.

By Carl Zimmer

*Business*

**In Coronavirus Vaccine Race, China Strays From the Official Paths**

Beijing is offering several vaccine candidates to employees of state-owned companies and the armed forces, while also conducting clinical trials in other countries.

By Sui-Lee Wee and Mariana Simões July 16

*Politics*

**Chief Vaccine Scientist Will Not Be Forced to Disclose Pharmaceutical Stocks**

Dr. Moncef Slaoui, the chief adviser for the Trump administration's coronavirus vaccine program, can remain a government contractor, thus shielding him from disclosure rules.

By Noah Weiland

**Washington Post**

<https://www.washingtonpost.com/>

*Accessed 18 July 2020*

*Social Issues*

**Anti-vaccination leaders fuel black mistrust of medical establishment as covid-19 kills people of color**

The memory of the horrific Tuskegee syphilis study makes some African Americans suspicious of a coronavirus vaccine

By Peter Jamison July 17, 2020

\* \* \* \*

**Think Tanks et al**

**Brookings**

<http://www.brookings.edu/>

*Accessed 18 July 2020*

[No new relevant content]

**Center for Global Development** [to 18 July 2020]

<http://www.cgdev.org/page/press-center>

*Accessed 18 July 2020*

[No new relevant content]

**Chatham House** [to 18 July 2020]

<https://www.chathamhouse.org/>

*Members Event*

**Webinar: Weekly COVID-19 Pandemic Briefing – Perspective from the Pharmaceutical Industry**

22 July 2020

As countries grapple with how best to tackle the COVID-19 pandemic and the reverberations it is sending through their societies and economies, understanding of how the virus is behaving, and what measures might best combat it, continues...

## **CSIS**

<https://www.csis.org/>

*Accessed 18 July 2020*

*Upcoming Event*

### **Online Event: A Conversation with Dr. Anthony Fauci**

July 24, 2020

*Newsletter*

### **Asia's Covid-19 Lessons for The West: Public Goods, Privacy, and Social Tagging**

July 16, 2020 | By [Victor Cha](#)

## **Council on Foreign Relations**

<http://www.cfr.org/>

*Accessed 18 July 2020*

*Global Governance*

### **The Politics of a COVID-19 Vaccine**

*Governments must prepare now to avoid "catastrophic success" once a Covid-19 vaccine emerges*

...No vaccine can be expected to produce complete or lasting immunity in all who take it. Millions will refuse to get vaccinated. And there is the brute fact that there are nearly eight billion men, women, and children on the planet. Manufacturing eight billion doses (or multiples of that if more than one dose is needed) of one or more vaccines and distributing them around the globe could require years, not months....

by Richard N. Haass July 14, 2020

## **Kaiser Family Foundation**

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Accessed 18 July 2020*

July 16, 2020 *News Release*

### **More Than 3 Million People Age 65 or Older Live with School-Age Children, and Could Be at Heightened Risk of COVID-19 Infection if Children Bring the Virus Home from School**

About 3.3 million adults age 65 or older live in a household with school-age children, a factor that state and local officials may want to take into account when deciding when and how fully to re-open schools this fall, a new KFF analysis finds. These older adults, who represent roughly...

*	*	*	*
*	*	*	*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an



*open access publication, subject to the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>). Copyright is retained by CVEP.*

*CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances. CVEP maintains an academic affiliation with the Division of Medical Ethics, NYU School of Medicine, and an operating affiliation with the Vaccine Education Center of Children’s Hospital of Philadelphia [CHOP].*

*Support for this service is provided by the Bill & Melinda Gates Foundation; PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi Pasteur U.S., Takeda, Moderna Therapeutics (list in formation).*

*Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.*

*	*	*	*
*	*	*	*